Navigation Links
Taxol with avastin produces noteworthy results
Date:12/27/2007

INDIANAPOLIS The positive results of the first nationwide clinical study showing the benefits of an antiangiogenic agent in breast cancer therapy are reported in the Dec. 27 issue of the New England Journal of Medicine.

The study with Avastin showed the biggest improvement in metastatic breast cancer ever reported in a chemotherapy-based clinical trial. It nearly doubled the time between initiation of chemotherapy for metastatic disease and progression of the breast cancer tumors.

The study was coordinated by the Eastern Cooperative Oncology Group (ECOG) and Kathy Miller, M.D., associate professor of medicine and Sheila D. Ward Scholar at the Indiana University School of Medicine, is the lead author.

Dr. Miller said she found the results exciting because this was the first study to show that an antiangiogenic agent can delay progression of advanced breast cancer. The study looked at Taxol (paclitaxel), which is one of the standard agents for metastatic disease, with and without the addition of Avastin (bevacizumab).

This study not only achieved the longest progression-free survival in advanced disease but the therapy achieved that improvement without adding to the day-to-day treatment burden and with only minor increases in toxicity, said Dr. Miller.

The study enrolled 722 women with metastatic disease from the United States, Canada, Peru and South Africa. Patients were randomized to one of two arms of the phase III study Taxol alone or Taxol with Avastin. The patients, who joined the study from December 2001 through May 2004, represented a balance of age, disease-free interval, estrogen-positive receptors and sites of disease.

The results show that treatment with Taxol and Avastin increased the period patients went without progression of their disease from 5.9 months to 11.8 months.

The next step is to move Avastin into the initial treatment of breast cancer in hopes that it will prevent recurrence in the first place, said Dr. Miller.

Avastin is a human monoclonal antibody that acts to reduce the development of blood vessels that feed tumors. Cancer tumors need an increasing supply of blood to grow and the development of the blood vessels to supply the tumor is a process called angiogenesis. Avastin already has been approved by the Food and Drug Administration for treatment of colorectal and lung cancer.

The first clinical study with Avastin in humans was done in 1997 at Indiana University School of Medicine by George W. Sledge Jr., M.D., a pioneer in the field of antiangiogenic research. Dr. Sledge, a breast cancer specialist and the Ballve-Lantero Professor of Oncology, also conducted a 1998 Avastin study for breast cancer patients. Both early studies produced positive results.


'/>"/>
Contact: Mary Hardin
mhardin@iupui.edu
317-274-7722
Indiana University
Source:Eurekalert

Related medicine news :

1. Taxol bristle ball: a wrench in the works for cancer
2. Taxol-type drugs give slight boost to survival rates in early breast cancer
3. FDA Panel Says No to Avastin for Advanced Breast Cancer
4. Stem cell research produces a key discovery for Fragile X Syndrome
5. Haemacure Reports Third Quarter 2007 Results
6. Brooke Franchise Corporation Announces Selected July Results
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
11. Martek Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... IL (PRWEB) , ... May 22, 2017 , ... ... is part of a larger group investing in InsightRX, an early stage company ... patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund acted ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pixel ... created specifically for use in Final Cut Pro X. The business-oriented elements and ... Pixel Film Studios’ ProParagraph Corporate will deliver a professional and distinguished look to ...
(Date:5/21/2017)... ... May 21, 2017 , ... For more than 20 years United Cutlery ... of knives and swords, from functional to fantasy. United Cutlery has always been “Stronger. ... designs that defy tradition. , Offering a range of weapons and tools built for ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... community, Queens University of Charlotte recently began recruitment efforts for the inaugural cohort ... students with the skills, knowledge and expertise to approach and address the unique ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Hill Agencies, a family managed firm that ... California Central Valley, is announcing a joint charity initiative with the Boys and Girls ... kid’s camp event. , The Boys and Girls Club of Kern County gives young ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)...  May is Stroke Awareness Month and Omron Healthcare ... methods to prevent a stroke: monitor and manage your ... and Prevention, undetected and uncontrolled hypertension is a leading ... leader in personal heart health technology, recently evolved its ... and stroke and is advancing a national public education ...
(Date:5/4/2017)... -- Fortuna Fix Inc. (" Fortuna "), a private, clinical-stage ... the need for embryonic and fetal stem cells by using ... Fortuna announced today the launch of its ... MD, PhD; Father Kevin FitzGerald , S.J., PhD; Col. ... James Giordano , PhD. "We are excited and ...
(Date:5/4/2017)... May 4, 2017 Clarius Mobile Health, ... handheld ultrasound scanners this week at the American ... (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians to ... rate, and evaluate pregnancy-related complications like ectopic pregnancy ...
Breaking Medicine Technology: